Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now directly owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded up $0.07 on Wednesday, hitting $21.25. The company had a trading volume of 1,245,656 shares, compared to its average volume of 1,173,671. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33. The stock has a 50 day moving average of $24.34 and a 200-day moving average of $24.88.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) earnings per share. Equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNLI. Rhumbline Advisers grew its stake in Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after purchasing an additional 22,900 shares during the period. TD Asset Management Inc increased its holdings in Denali Therapeutics by 4.5% during the second quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock worth $4,160,000 after buying an additional 7,766 shares during the last quarter. Arizona State Retirement System raised its position in Denali Therapeutics by 9.0% in the second quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after acquiring an additional 2,730 shares during the period. American Century Companies Inc. boosted its stake in Denali Therapeutics by 13.7% in the second quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after acquiring an additional 63,058 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after acquiring an additional 84,522 shares during the period. 92.92% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on DNLI. Robert W. Baird assumed coverage on Denali Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $31.00 target price on the stock. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.